Eli Lilly and Company

LLY

US5324571083

Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows: - endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems; - oncology (19.5%); - immunology diseases (11.1%); - neurology (8.4%): primarily drugs used in treating depression and schizophrenia; - other (3.3%). Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).

Sector

Pharmaceuticals

Calendar

2024-08-08 - Q2 2024 Earnings Release

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

David Ricks, CEO of Eli Lilly: A market of over a billion people

March 12, 2024 at 02:47 pm EDT

More Strategies

Ratings for Eli Lilly and Company

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

934.1 USD

Average target price

894.8 USD

Spread / Average Target

-4.21%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+62.66%	841B
NOVO NORDISK A/S	+40.42%	625B
JOHNSON & JOHNSON	-4.37%	360B
MERCK & CO., INC.	+17.16%	327B
ABBVIE INC.	+9.87%	300B
ASTRAZENECA PLC	+15.66%	242B
NOVARTIS AG	+17.90%	227B
AMGEN INC.	+14.86%	174B
PFIZER, INC.	+0.45%	162B
SANOFI	+5.17%	127B

Other Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:03 2024-07-12 pm EDT			After market 06:03:27 pm
948.2 ^USD	+1.50%		948.3	+0.01%

Jul. 12	Novo Nordisk faces scrutiny on Capitol Hill for pulling Levemir insulin from US market	RE
Jul. 12	Ozempic linked with lower dementia risk, nicotine use, British study finds	RE

Novo Nordisk faces scrutiny on Capitol Hill for pulling Levemir insulin from US market	Jul. 12	RE
Ozempic linked with lower dementia risk, nicotine use, British study finds	Jul. 12	RE
EU Drug Regulator Issues New Safety Measures for GLP-1 Drugs Amid Aspiration Risk Concerns	Jul. 12	MT
UBS Raises Price Target on Eli Lilly to $1,100 From $910, Maintains Buy Rating	Jul. 12	MT
Patients on weight-loss drugs should inform doctor before surgery, EU regulator says	Jul. 12	RE
Health Care Up as Obesity-Drug Wars Continue -- Health Care Roundup	Jul. 11	DJ
Pfizer moves forward with once-daily weight loss drug	Jul. 11	RE
JPMorgan Adjusts Price Target on Eli Lilly and Co. to $1,000 From $900, Maintains Overweight Rating	Jul. 11	MT
Morgan Stanley Adjusts Price Target on Eli Lilly and Co. to $1,083 From $1,023, Maintains Overweight Rating	Jul. 11	MT
Berenberg Adjusts Price Target on Eli Lilly & Co. to $1,000 From $850, Maintains Buy Rating	Jul. 11	MT
US Senator Sanders optimistic Novo Nordisk can be pressured to cut Wegovy, Ozempic prices	Jul. 10	RE
SANDERS SAYS HE IS CURRENTLY FOCUSED ON NOVO NORDISK BUT WILL 'C…	Jul. 10	RE
Eli Lilly Names Gordon Brooks Interim Chief Financial Officer	Jul. 10	DJ
Eli Lilly Appoints Gordon Brooks Interim CFO	Jul. 10	MT
Barclays Adjusts Price Target on Eli Lilly to $1,025 From $913	Jul. 10	MT
Eli Lilly Names Gordon Brooks Interim CFO	Jul. 10	MT
DexCom, Inc. : A Must-Have Tool for Diabetes Care	Jul. 10
Analysis Shows Use of Novo Nordisk's Wegovy, Ozempic for Weight Loss Declines After Two Years	Jul. 10	MT
Sellers of fake Ozempic to face charges in Austrian court	Jul. 09	RE
Mixed feelings	Jul. 09
VYNE Therapeutics Inc. Announces Appointment of Subhashis Banerjee, M.D. as Senior Vice President of Clinical Development	Jul. 09	CI
Eli Lilly's Mounjaro Provides Better Weight Loss Compared to Semaglutide-Based Drugs, Study Shows	Jul. 09	MT
Novo Nordisk shares down after analysis finds Lilly drug leads to better weight loss	Jul. 09	RE
Health Care Flat Amid Deal Activity -- Health Care Roundup	Jul. 08	DJ
S&P 500, Nasdaq Extend Record Closing Runs	Jul. 08	MT